|
1
|
Cruz Walma DA, Chen Z, Bullock AN and
Yamada KM: Ubiquitin ligases: Guardians of mammalian development.
Nat Rev Mol Cell Biol. 23:350–367. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buetow L and Huang DT: Structural insights
into the catalysis and regulation of E3 ubiquitin ligases. Nat Rev
Mol Cell Biol. 17:626–642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sheng X, Xia Z, Yang H and Hu R: The
ubiquitin codes in cellular stress responses. Protein Cell.
15:157–190. 2024. View Article : Google Scholar :
|
|
4
|
Sampson C, Wang Q, Otkur W, Zhao H, Lu Y,
Liu X and Piao HL: The roles of E3 ubiquitin ligases in cancer
progression and targeted therapy. Clin Transl Med. 13:e12042023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berndsen CE and Wolberger C: New insights
into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol.
21:301–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciechanover A: The unravelling of the
ubiquitin system. Nat Rev Mol Cell Biol. 16:322–324. 2015.
View Article : Google Scholar : PubMed/NCBI
Morreale FE and Walden H: Types of
ubiquitin ligases. Cell. 165:248–248.e1. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asmamaw MD, Liu Y, Zheng YC, Shi XJ and
Liu HM: Skp2 in the ubiquitin-proteasome system: A comprehensive
review. Med Res Rev. 40:1920–1949. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bernassola F, Chillemi G and Melino G:
HECT-type E3 ubiquitin ligases in cancer. Trends Biochem Sci.
44:1057–1075. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Metzger MB, Hristova VA and Weissman AM:
HECT and RING finger families of E3 ubiquitin ligases at a glance.
J Cell Sci. 125:531–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah SS and Kumar S: Adaptors as the
regulators of HECT ubiquitin ligases. Cell Death Differ.
28:455–472. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goto J, Otaki Y, Watanabe T and Watanabe
M: The role of HECT-Type E3 ligase in the development of cardiac
disease. Int J Mol Sci. 22:60652021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Filali-Mouncef Y, Hunter C, Roccio F,
Zagkou S, Dupont N, Primard C, Proikas-Cezanne T and Reggiori F:
The ménage à trois of autophagy, lipid droplets and liver disease.
Autophagy. 18:50–72. 2022. View Article : Google Scholar :
|
|
13
|
You Y, Gao C, Wu J, Qu H, Xiao Y, Kang Z,
Li J and Hong J: Enhanced expression of ARK5 in hepatic stellate
cell and hepatocyte synergistically promote liver fibrosis. Int J
Mol Sci. 23:130842022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maghames CM, Lobato-Gil S, Perrin A,
Trauchessec H, Rodriguez MS, Urbach S, Marin P and Xirodimas DP:
NEDDylation promotes nuclear protein aggregation and protects the
ubiquitin proteasome system upon proteotoxic stress. Nat Commun.
9:43762018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mishra A, Godavarthi SK, Maheshwari M,
Goswami A and Jana NR: The ubiquitin ligase E6-AP is induced and
recruited to aggresomes in response to proteasome inhibition and
may be involved in the ubiquitination of Hsp70-bound misfolded
proteins. J Biol Chem. 284:10537–10545. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Chen Y, Huang Q, Liu W, Ji X, Hu F,
Zhu Y, Zhang L and Dong G: IRAK2 counterbalances oncogenic Smurf1
in colon cancer cells by dictating ER stress. Cell Signal.
48:69–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo X, Shen S, Song S, He S, Cui Y, Xing
G, Wang J, Yin Y, Fan L, He F and Zhang L: The E3 ligase Smurf1
regulates Wolfram syndrome protein stability at the endoplasmic
reticulum. J Biol Chem. 286:18037–18047. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rinella ME, Lazarus JV, Ratziu V, Francque
SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab
JP, et al: A multisociety Delphi consensus statement on new fatty
liver disease nomenclature. Hepatology. 78:1966–1986. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rotin D and Kumar S: Physiological
functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell
Biol. 10:398–409. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huibregtse JM, Scheffner M, Beaudenon S
and Howley PM: A family of proteins structurally and functionally
related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci
USA. 92:2563–2567. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang L, Kinnucan E, Wang G, Beaudenon S,
Howley PM, Huibregtse JM and Pavletich NP: Structure of an
E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3
enzyme cascade. Science. 286:1321–1326. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maspero E, Mari S, Valentini E, Musacchio
A, Fish A, Pasqualato S and Polo S: Structure of the HECT:Ubiquitin
complex and its role in ubiquitin chain elongation. EMBO Rep.
12:342–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scheffner M and Kumar S: Mammalian HECT
ubiquitin-protein ligases: Biological and pathophysiological
aspects. Biochim Biophys Acta. 1843:61–74. 2024. View Article : Google Scholar
|
|
24
|
Zheng N and Shabek N: Ubiquitin ligases:
Structure, function, and regulation. Annu Rev Biochem. 86:129–157.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Trotman LC, Koppie T, Alimonti A,
Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo
C, et al: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.
Cell. 128:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Staub O, Dho S, Henry P, Correa J,
Ishikawa T, McGlade J and Rotin D: WW domains of Nedd4 bind to the
proline-rich PY motifs in the epithelial Na+ channel deleted in
Liddle's syndrome. EMBO J. 15:2371–2380. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song MS and Pandolfi PP: The HECT family
of E3 ubiquitin ligases and PTEN. Semin Cancer Biol. 85:43–51.
2022. View Article : Google Scholar
|
|
28
|
Shearwin-Whyatt L, Dalton HE, Foot N and
Kumar S: Regulation of functional diversity within the Nedd4 family
by accessory and adaptor proteins. Bioessays. 28:617–628. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sala-Gaston J, Costa-Sastre L, Pedrazza L,
Martinez-Martinez A, Ventura F and Rosa JL: Regulation of MAPK
signaling pathways by the large HERC ubiquitin ligases. Int J Mol
Sci. 24:49062023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
García-Cano J, Martinez-Martinez A,
Sala-Gaston J, Pedrazza L and Rosa JL: HERCing: Structural and
functional relevance of the large HERC ubiquitin ligases. Front
Physiol. 10:10142019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pérez-Villegas EM, Ruiz R, Bachiller S,
Ventura F, Armengol JA and Rosa JL: The HERC proteins and the
nervous system. Semin Cell Dev Biol. 132:5–15. 2022. View Article : Google Scholar
|
|
32
|
Kao SH, Wu HT and Wu KJ: Ubiquitination by
HUWE1 in tumorigenesis and beyond. J Biomed Sci. 25:672018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qi L, Xu X and Qi X: The giant E3 ligase
HUWE1 is linked to tumorigenesis, spermatogenesis, intellectual
disability, and inflammatory diseases. Front Cell Infect Microbiol.
12:9059062022. View Article : Google Scholar :
|
|
34
|
Wenmaekers S, Viergever BJ, Kumar G,
Kranenburg O, Black PC, Daugaard M and Meijer RP: A potential role
for HUWE1 in modulating cisplatin sensitivity. Cells. 10:12622021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yuan B, Liu J, Cao J, Yu Y, Zhang H, Wang
F, Zhu Y, Xiao M, Liu S, Ye Y, et al: PTPN3 acts as a tumor
suppressor and boosts TGF-β signaling independent of its
phosphatase activity. EMBO J. 38:e999452019. View Article : Google Scholar
|
|
36
|
Hagström H, Vessby J, Ekstedt M and Shang
Y: 99% of patients with NAFLD meet MASLD criteria and natural
history is therefore identical. J Hepatol. 80:e76–e77. 2024.
View Article : Google Scholar
|
|
37
|
Wong VW, Ekstedt M, Wong GL and Hagström
H: Changing epidemiology, global trends and implications for
outcomes of NAFLD. J Hepatol. 79:842–852. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
European Association for the Study of the
Liver (EASL); European Association for the Study of Diabetes
(EASD); European Association for the Study of Diabetes (EASD);
European Association for the Study of Obesity (EASO):
EASL-EASD-EASO clinical practice guidelines on the management of
metabolic dysfunction-associated steatotic liver disease (MASLD). J
Hepatol. 81:492–542. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Targher G, Byrne CD and Tilg H: MASLD: A
systemic metabolic disorder with cardiovascular and malignant
complications. Gut. 73:691–702. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu S, Zhu Y, Zhao X, Li R, Shao G, Gong D,
Hu C, Liu H, Xu K, Liu C, et al: Hepatocytic lipocalin-2 controls
HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice.
Dev Cell. 58:2326–2337.e5. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan C, Zhao M, Li S, Liu T, Xu C, Liu L,
Geng T and Gong D: Increase of E3 ubiquitin ligase NEDD4 expression
leads to degradation of its target proteins PTEN/IGF1R during the
formation of goose fatty liver. J Anim Sci. 98:skaa2702020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao HJ, Jiang H, Ding K, Qiu XS, Ma N,
Zhang FK, Wang YK, Zheng QW, Xia J, Ni QZ, et al: ARID2 mitigates
hepatic steatosis via promoting the ubiquitination of JAK2. Cell
Death Differ. 30:383–396. 2023. View Article : Google Scholar
|
|
43
|
Jiang L, Zhao J, Yang Q, Li M, Liu H, Xiao
X, Tian S, Hu S, Liu Z, Yang P, et al: Lysosomal-associated protein
transmembrane 5 ameliorates non-alcoholic steatohepatitis by
promoting the degradation of CDC42 in mice. Nat Commun.
14:26542023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao GN, Zhang P, Gong J, Zhang XJ, Wang
PX, Yin M, Jiang Z, Shen LJ, Ji YX, Tong J, et al: Tmbim1 is a
multivesicular body regulator that protects against non-alcoholic
fatty liver disease in mice and monkeys by targeting the lysosomal
degradation of Tlr4. Nat Med. 23:742–752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Marino A, Menghini R, Fabrizi M,
Casagrande V, Mavilio M, Stoehr R, Candi E, Mauriello A,
Moreno-Navarrete JM, Gómez-Serrano M, et al: ITCH deficiency
protects from diet-induced obesity. Diabetes. 63:550–561. 2014.
View Article : Google Scholar
|
|
46
|
Stöhr R, Mavilio M, Marino A, Casagrande
V, Kappel B, Möllmann J, Menghini R, Melino G and Federici M: ITCH
modulates SIRT6 and SREBP2 to influence lipid metabolism and
atherosclerosis in ApoE null mice. Sci Rep. 5:90232015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang H, Peng B, Chen Q, Wang Y and Li R:
Long non-coding RNA nuclear-enriched abundant transcript 1 (NEAT1)
facilitates foam cell formation and atherosclerosis progression
through the miR-17-5p/Itchy E3 ubiquitin protein ligase
(ITCH)/liver kinase B1 (LKB1) axis. Circ J. 88:1697–1708. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Menghini R, Hoyles L, Cardellini M,
Casagrande V, Marino A, Gentileschi P, Davato F, Mavilio M, Arisi
I, Mauriello A, et al: ITCH E3 ubiquitin ligase downregulation
compromises hepatic degradation of branched-chain amino acids. Mol
Metab. 59:1014542022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hooper C, Puttamadappa SS, Loring Z,
Shekhtman A and Bakowska JC: Spartin activates
atrophin-1-interacting protein 4 (AIP4) E3 ubiquitin ligase and
promotes ubiquitination of adipophilin on lipid droplets. BMC Biol.
8:722010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin W, Zhang X, Zhang C, Li L, Zhang J,
Xie P, Zhan Y and An W: Deletion of Smurf1 attenuates liver
steatosis via stabilization of p53. Lab Invest. 102:1075–1087.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang X, Zhan Y, Lin W, Zhao F, Guo C,
Chen Y, Du M, Li D, Zhang L, An W, et al: Smurf1 aggravates
non-alcoholic fatty liver disease by stabilizing SREBP-1c in an E3
activity-independent manner. FASEB J. 34:7631–7643. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhu K, Tang Y, Xu X, Dang H, Tang LY, Wang
X, Wang XW and Zhang YE: Non-proteolytic ubiquitin modification of
PPARγ by Smurf1 protects the liver from steatosis. PLoS Biol.
16:e30000912018. View Article : Google Scholar
|
|
53
|
Petrasek J, Erhartova D and Levine B:
Protective effect of SMAD-specific E3 ubiquitin protein ligase 1 in
alcoholic steatohepatitis in mice. Hepatol Commun. 3:1450–1458.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhu Q, Wang D, Liang F, Tong X, Liang Z,
Wang X, Chen Y and Mo D: Protein arginine methyltransferase PRMT1
promotes adipogenesis by modulating transcription factors C/EBPβ
and PPARγ. J Biol Chem. 298:1023092022. View Article : Google Scholar
|
|
55
|
Nozaki Y, Kobayashi M, Wakasawa H, Hoshino
S, Suwa F, Ose Y, Tagawa R and Higami Y: Systemic depletion of WWP1
improves insulin sensitivity and lowers triglyceride content in the
liver of obese mice. FEBS Open Bio. 13:1086–1094. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Feng WW, Bang S, Takacs EM, Day C,
Crawford KJ, Al-Sheyab R, Almufarrej DB, Wells W, Ilchenko S,
Kasumov T, et al: Hepatic Huwe1 loss protects mice from
non-alcoholic fatty liver disease through lipid metabolic rewiring.
iScience. 26:1084052023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhao Z, Xu D, Wang Z, Wang L, Han R, Wang
Z, Liao L and Chen Y: Hepatic PPARα function is controlled by
polyubiquitination and proteasome-mediated degradation through the
coordinated actions of PAQR3 and HUWE1. Hepatology. 68:289–303.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lin Y, Chen L, You X, Li Z, Li C and Chen
Y: PAQR9 regulates hepatic ketogenesis and fatty acid oxidation
during fasting by modulating protein stability of PPARα. Mol Metab.
53:1013312021. View Article : Google Scholar
|
|
59
|
Luo X, Li Z, Chen L, Zhang X, Zhu X, Wang
Z and Chen Y: Monocarboxylate transporter 1 in the liver modulates
high-fat diet-induced obesity and hepatic steatosis in mice.
Metabolism. 143:1555372023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wan W, You Z, Zhou L, Xu Y, Peng C, Zhou
T, Yi C, Shi Y and Liu W: mTORC1-regulated and HUWE1-mediated WIPI2
degradation controls autophagy flux. Mol Cell. 72:303–315.e6. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Peng K, Wang S, Liu R, Zhou L, Jeong GH,
Jeong IH, Liu X, Kiyokawa H, Xue B, Zhao B, et al: Effects of UBE3A
on cell and liver metabolism through the ubiquitination of PDHA1
and ACAT1. Biochemistry. 62:1274–1286. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guo Q, Xin M, Lu Q, Feng D, Yang V, Peng
LF, Whelan KA, Hu W, Wu S, Yang X, et al: A novel NEDD4L-TXNIP-CHOP
axis in the pathogenesis of nonalcoholic steatohepatitis.
Theranostics. 13:2210–2225. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li Z, Zhao J, Wu Y, Fan S, Yuan H, Xia J,
Hu L, Yang J, Liu J, Wu X, et al: TRAF2 decrease promotes the
TGF-β-mTORC1 signal in MAFLD-HCC through enhancing AXIN1-mediated
Smad7 degradation. FASEB J. 38:e234912024. View Article : Google Scholar
|
|
64
|
Li T, Liu R, Cao H, Deng S, Wang G, Wang
X, Zhao P, Li X, Zhu J, Shao S, et al: Epithelial membrane protein
1 drives hepatic stellate cell activation via the TLN1/FAK cascade
in MASLD donor liver transplantation. Mol Biomed. 6:1162025.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu D, Chen L, Wang Z, Li Z, Liu L and
Peng L: Ubiquitination of TFEB increased intestinal permeability to
aggravate metabolic dysfunction-associated steatohepatitis.
Hepatology. 82:1534–1550. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang Y, Zhan C, Chen G and Sun J:
Label-free quantitative proteomics and bioinformatics analyses of
alcoholic liver disease in a chronic and binge mouse model. Mol Med
Rep. 18:2079–2087. 2018.PubMed/NCBI
|
|
67
|
Horn P and Tacke F: Metabolic
reprogramming in liver fibrosis. Cell Metab. 36:1439–1455. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Song Y, Wei J, Li R, Fu R, Han P, Wang H,
Zhang G, Li S, Chen S, Liu Z, et al: Tyrosine kinase receptor B
attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling.
Hepatology. 78:1433–1447. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen C, Bi Y, Chen B and He S: Nedd4L
signaling contributes to carbon tetrachloride-induced liver
fibrosis in female mice and is associated with enteric
dysbacteriosis. Gastroenterol Rep (Oxf). 13:goaf0222025. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ge MX, Liu HT, Zhang N, Niu WX, Lu ZN, Bao
YY, Huang R, Yu DK, Shao RG and He HW: Costunolide represses
hepatic fibrosis through WW domain-containing protein 2-mediated
Notch3 degradation. Br J Pharmacol. 177:372–387. 2020. View Article : Google Scholar
|
|
71
|
Shen J, Wang Z, Liu M, Zhu YJ, Zheng L,
Wang LL, Cheng JL, Liu TT, Zhang GD, Yang TY, et al:
LincRNA-ROR/miR-145/ZEB2 regulates liver fibrosis by modulating
HERC5-mediated p53 ISGylation. FASEB J. 37:e229362023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Guo Y, Zhao C, Dai W, Wang B, Lai E, Xiao
Y, Tang C, Huang Z and Gao J: C-C motif chemokine receptor 2
inhibition reduces liver fibrosis by restoring the immune cell
landscape. Int J Biol Sci. 19:2572–2587. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kim JY, Kim KM, Yang JH, Cho SS, Kim SJ,
Park SJ, Ahn SG, Lee GH, Yang JW, Lim SC, et al: Induction of E6AP
by microRNA-302c dysregulation inhibits TGF-β-dependent
fibrogenesis in hepatic stellate cells. Sci Rep. 10:4442020.
View Article : Google Scholar
|
|
74
|
Zhang N, Yang P, Li Y, Ouyang Q, Hou F,
Zhu G, Zhang B, Huang J, Jia J and Xu A: Serum iron overload
activates the SMAD pathway and hepcidin expression of hepatocytes
via SMURF1. J Clin Transl Hepatol. 12:227–235. 2024.PubMed/NCBI
|
|
75
|
Lee H, Yu DM, Bahn MS, Kwon YJ, Um MJ,
Yoon SY, Kim KT, Lee MW, Jo SJ, Lee S, et al: Hepatocyte-specific
prominin-1 protects against liver injury-induced fibrosis by
stabilizing SMAD7. Exp Mol Med. 54:1277–1289. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Cai Y, Zhou CH, Fu D and Shen XZ:
Overexpression of Smad ubiquitin regulatory factor 2 suppresses
transforming growth factor-β mediated liver fibrosis. J Dig Dis.
13:327–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cai Y, Huang G, Ma L, Dong L, Chen S, Shen
X and Zhang S, Xue R, Sun D and Zhang S: Smurf2, an E3 ubiquitin
ligase, interacts with PDE4B and attenuates liver fibrosis through
miR-132 mediated CTGF inhibition. Biochim Biophys Acta Mol Cell
Res. 1865:297–308. 2018. View Article : Google Scholar
|
|
78
|
Jiang XL, Liu C, Zhan ZY, Lan XQ, Wu YL,
Nan JX, Jin CH and Lian LH: Thiazole isomers as potential ALK5
inhibitors alleviate P2X7R-mediated inflammation during liver
fibrosis. Int Immunopharmacol. 153:1144722025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kong D, Zhang Z, Chen L, Huang W, Zhang F,
Wang L, Wang Y, Cao P and Zheng S: Curcumin blunts
epithelial-mesenchymal transition of hepatocytes to alleviate
hepatic fibrosis through regulating oxidative stress and autophagy.
Redox Biol. 36:1016002020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Danpanichkul P, Suparan K, Kaeosri C,
Jatupornpakdee P, Attia AM, Suenghataiphorn T, Thongpiya J,
Sukphutanan B, Huang DQ, Noureddin M, et al: Global trend of
MASH-associated liver cancer: A systematic analysis from the global
burden of disease 2021. Clin Gastroenterol Hepatol. 23:1346–1355.
2025. View Article : Google Scholar
|
|
81
|
Cao X, Chen Y, Chen Y and Jiang M: The
role of tripartite motif family proteins in chronic liver diseases:
Molecular mechanisms and therapeutic potential. Biomolecules.
14:10382024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang Z, Kawaguchi K, Honda M, Hashimoto S,
Shirasaki T, Okada H, Orita N, Shimakami T, Yamashita T, Sakai Y,
et al: Notch signaling facilitates hepatitis B virus covalently
closed circular DNA transcription via cAMP response element-binding
protein with E3 ubiquitin ligase-modulation. Sci Rep. 9:16212019.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bawono RG, Abe T, Qu M, Kuroki D, Deng L,
Matsui C, Ryo A, Suzuki T, Matsuura Y, Sugiyama M, et al: HERC5 E3
ligase mediates ISGylation of hepatitis B virus X protein to
promote viral replication. J Gen Virol. 102:2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Langerová H, Lubyová B, Zábranský A,
Hubálek M, Glendová K, Aillot L, Hodek J, Strunin D, Janovec V,
Hirsch I and Weber J: Hepatitis B core protein is
post-translationally modified through K29-linked ubiquitination.
Cells. 9:25472020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wan T, Lei Z, Tu B, Wang T, Wang J and
Huang F: NEDD4 induces K48-linked degradative ubiquitination of
hepatitis B virus x protein and inhibits HBV-associated HCC
progression. Front Oncol. 11:6251692021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rost M, Mann S, Lambert C, Döring T, Thomé
N and Prange R: Gamma-adaptin, a novel ubiquitin-interacting
adaptor, and Nedd4 ubiquitin ligase control hepatitis B virus
maturation. J Biol Chem. 281:29297–29308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lambert C, Döring T and Prange R:
Hepatitis B virus maturation is sensitive to functional inhibition
of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol. 81:9050–9060.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zheng Y, Wang M, Li S, Bu Y, Xu Z, Zhu G,
Wu C, Zhao K, Li A, Chen Q, et al: Hepatitis B virus hijacks TSG101
to facilitate egress via multiple vesicle bodies. PLoS Pathog.
19:e10113822023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lim HY, Han J, Yoon H and Jang KL: Tumor
suppressor p53 inhibits hepatitis B virus replication by
downregulating HBx via E6AP-mediated proteasomal degradation in
human hepatocellular carcinoma cell lines. Viruses. 14:23132022.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Han J and Jang KL: All-trans retinoic acid
downregulates HBx levels via E6-associated protein-mediated
proteasomal degradation to suppress hepatitis B virus replication.
PLoS One. 19:e03053502024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Deng L, Liang Y, Ariffianto A, Matsui C,
Abe T, Muramatsu M, Wakita T, Maki M, Shibata H and Shoji I:
Hepatitis C virus-induced ROS/JNK signaling pathway activates the
E3 ubiquitin ligase itch to promote the release of HCV particles
via polyubiquitylation of VPS4A. J Virol. 96:e01811212022.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Domingues P, Bamford CGG, Boutell C and
McLauchlan J: Inhibition of hepatitis C virus RNA replication by
ISG15 does not require its conjugation to protein substrates by the
HERC5 E3 ligase. J Gen Virol. 96:3236–3242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Abe T, Minami N, Bawono RG, Matsui C, Deng
L, Fukuhara T, Matsuura Y and Shoji I: ISGylation of hepatitis C
virus NS5A protein promotes viral RNA replication via recruitment
of cyclophilin A. J Virol. 94:e00532–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Munakata T, Liang Y, Kim S, McGivern DR,
Huibregtse J, Nomoto A and Lemon SM: Hepatitis C virus induces
E6AP-dependent degradation of the retinoblastoma protein. PLoS
Pathog. 3:1335–1347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Shirakura M, Murakami K, Ichimura T,
Suzuki R, Shimoji T, Fukuda K, Abe K, Sato S, Fukasawa M, Yamakawa
Y, et al: E6AP ubiquitin ligase mediates ubiquitylation and
degradation of hepatitis C virus core protein. J Virol.
81:1174–1185. 2007. View Article : Google Scholar :
|
|
96
|
Moriishi K, Shoji I, Mori Y, Suzuki R,
Suzuki T, Kataoka C and Matsuura Y: Involvement of PA28gamma in the
propagation of hepatitis C virus. Hepatology. 52:411–420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kwak J, Shim JH, Tiwari I and Jang KL:
Hepatitis C virus core protein inhibits E6AP expression via DNA
methylation to escape from ubiquitin-dependent proteasomal
degradation. Cancer Lett. 380:59–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yoon H and Jang KL: Hydrogen peroxide
inhibits hepatitis C virus replication by downregulating hepatitis
C virus core levels through e6-associated protein-mediated
proteasomal degradation. Cells. 13:622023. View Article : Google Scholar
|
|
99
|
Park JM, Yoon H, Jeong Y and Jang KL:
Tumour suppressor p53 inhibits hepatitis C virus replication by
inducing E6AP-mediated proteasomal degradation of the viral core
protein. FEBS Lett. 596:2525–2537. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Lee HK, Yoon H and Jang KL: All-trans
retinoic acid inhibits HCV replication by downregulating core
levels via E6AP-mediated proteasomal degradation. Biochem Biophys
Res Commun. 594:15–21. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Verga-Gérard A, Porcherot M,
Meyniel-Schicklin L, André P, Lotteau V and Perrin-Cocon L:
Hepatitis C virus/human interactome identifies SMURF2 and the viral
protease as critical elements for the control of TGF-β signaling.
FASEB J. 27:4027–4040. 2013. View Article : Google Scholar
|
|
102
|
Wang Z, Gao Y, Zhang C, Hu H, Guo D, Xu Y,
Xu Q, Zhang W, Deng S, Lv P, et al: Quinolinate
phosphoribosyltransferase is an antiviral host factor against
hepatitis C virus infection. Sci Rep. 7:58762017. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Shirasaki T, González-López O, McKnight
KL, Xie L, Shiota T, Chen X, Feng H and Lemon SM: Nonlytic
quasi-enveloped hepatovirus release is facilitated by pX protein
interaction with the E3 ubiquitin ligase ITCH. J Virol.
96:e01195222022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang H, Li Q, Tang Q, Shi G, Wu G, Mao X,
Wu C, Zhang L, Liu J, Li J and Li B: Role and therapeutic potential
of E3s in the tumor microenvironment of hepatocellular carcinoma.
Front Immunol. 15:14837212024. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Miao Y, Wang S, Zhang J, Liu H, Zhang C,
Jin S and Bai D: Strategic advancement of E3 ubiquitin ligase in
the management of hepatocellular carcinoma. Med Oncol. 41:1782024.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hang X, Zhu S, Di H, Wu Z, Chu K, Wang J,
Xin H, Yu G, Peng H, Miao X and Xu W: NEDD4 depletion inhibits
hepatocellular carcinoma growth via targeting PTEN. Cell Physiol
Biochem. 39:768–779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang ZJ, Zhu JJ, Yang XY and Biskup E:
NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT
signaling in hepatocellular carcinoma. Oncol Lett. 14:2649–2656.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhou Y, Qiu J, Liu S, Wang P, Ma D, Zhang
G, Cao Y, Hu L, Wang Z, Wu J and Jiang C: CFDP1 promotes
hepatocellular carcinoma progression through activating
NEDD4/PTEN/PI3K/AKT signaling pathway. Cancer Med. 12:425–444.
2023. View Article : Google Scholar :
|
|
109
|
Zheng H, Ke X, Li D and Wang Q, Wang J,
Liu X, Deng M, Deng X, Xue Y, Zhu Y and Wang Q: NEDD4 promotes cell
growth and motility in hepatocellular carcinoma. Cell Cycle.
17:728–738. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Li K, Niu Y, Yuan Y, Qiu J, Shi Y, Zhong
C, Qiu Z, Li K, Lin Z, Huang Z, et al: Insufficient ablation
induces E3-ligase Nedd4 to promote hepatocellular carcinoma
progression by tuning TGF-β signaling. Oncogene. 41:3197–3209.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Liu Y, Hu X, Zhou S, Sun T, Shen F and
Zeng L: Golgi protein 73 promotes angiogenesis in hepatocellular
carcinoma. Research (Wash D C). 7:04252024.PubMed/NCBI
|
|
112
|
Dong R, Fei Y, He Y, Gao P, Zhang B, Zhu
M, Wang Z, Wu L, Wu S, Wang X, et al: Lactylation-driven HECTD2
limits the response of hepatocellular carcinoma to lenvatinib. Adv
Sci (Weinh). 12:e24125592025. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu F, Yang W, Hu M, Zhang Y, Sun B, Yang
H, Brosius J and Deng C: Constitutive activity of GPR26 regulated
by ubiquitin-dependent degradation and its antitumor role. FEBS J.
288:4655–4682. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wu Y, Xiang Q, Lv X, Xiang X, Feng Z, Tian
S, Tang J, Xiang T and Gong J: C2orf40 inhibits hepatocellular
carcinoma through interaction with UBR5. J Gastroenterol Hepatol.
36:2581–2591. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang M, Ma X, Wang G, Song Y, Zhang M, Mai
Z, Zhou B, Ye Y and Xia W: Targeting UBR5 in hepatocellular
carcinoma cells and precise treatment via echinacoside
nanodelivery. Cell Mol Biol Lett. 27:922022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Leboeuf D, Abakumova T, Prikazchikova T,
Rhym L, Anderson DG, Zatsepin TS and Piatkov KI: Downregulation of
the Arg/N-degron pathway sensitizes cancer cells to chemotherapy in
vivo. Mol Ther. 28:1092–1104. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gao ZF, Wu YN, Bai ZT, Zhang L, Zhou Q and
Li X: Tumor-suppressive role of HACE1 in hepatocellular carcinoma
and its clinical significance. Oncol Rep. 36:3427–3435. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wu M, Zhou X, Zhou X, Wang G, Zeng Y, Li
J, Prochownik EV, Wang F and Li Y: ZDHHC3-mediated SCAP S-acylation
promotes cholesterol biosynthesis and tumor immune escape in
hepatocellular carcinoma. Cell Rep. 43:1149622024. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhang Y, Chen S, You L, He Z, Xu P and
Huang W: LINC00161 upregulated by M2-like tumor-associated
macrophages promotes hepatocellular carcinoma progression by
methylating HACE1 promoters. Cytotechnology. 76:777–793. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lee HS, Park MH, Yang SJ, Park KC, Kim NS,
Kim YS, Kim DI, Yoo HS, Choi EJ and Yeom YI: Novel candidate
targets of Wnt/beta-catenin signaling in hepatoma cells. Life Sci.
80:690–698. 2007. View Article : Google Scholar
|
|
121
|
Zhao F, Gong X, Liu A, Lv X, Hu B and
Zhang H: Downregulation of Nedd4L predicts poor prognosis, promotes
tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular
carcinoma. Biochem Biophys Res Commun. 495:1136–1143. 2018.
View Article : Google Scholar
|
|
122
|
Bian S, Ni W, Zhou L, Tong Y, Dai C, Zhao
X, Qiang Y, Gao J, Xiao Y, Liu W, et al: Ubiquitin-specific
protease 1 facilitates hepatocellular carcinoma progression by
modulating mitochondrial fission and metabolic reprogramming via
cyclin-dependent kinase 5 stabilization. Cell Death Differ.
31:1202–1218. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ge QY, Chen J, Li GX, Tan XL, Song J, Ning
D, Mo J, Du PC, Liu QM, Liang HF, et al: GRAMD4 inhibits tumour
metastasis by recruiting the E3 ligase ITCH to target TAK1 for
degradation in hepatocellular carcinoma. Clin Transl Med.
11:e6352021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Chen S, Zhou B, Huang W, Li Q, Yu Y, Kuang
X, Huang H, Wang W and Xie P: The deubiquitinating enzyme USP44
suppresses hepatocellular carcinoma progression by inhibiting
Hedgehog signaling and PDL1 expression. Cell Death Dis. 14:8302023.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Cheng Q, Cao X, Yuan F, Li G and Tong T:
Knockdown of WWP1 inhibits growth and induces apoptosis in hepatoma
carcinoma cells through the activation of caspase3 and p53. Biochem
Biophys Res Commun. 448:248–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yang W, Wang B, Yu Q, Liu T, Li T, Tian T,
Jin A, Ding L, Chen W, Wang H, et al: ARHGAP24 represses β-catenin
transactivation-induced invasiveness in hepatocellular carcinoma
mainly by acting as a GTPase-independent scaffold. Theranostics.
12:6189–6206. 2022. View Article : Google Scholar
|
|
127
|
Zhu Q, Yuan Z, Huo Q, Lu Q, Wu Q, Guo J,
Fu W, Lu Y, Zhong L, Shang W, et al: YY1 induced USP13
transcriptional activation drives the malignant progression of
hepatocellular carcinoma by deubiquitinating WWP1. Cell Mol Biol
Lett. 30:562025. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Fang S, Zhang D, Weng W, Lv X, Zheng L,
Chen M, Fan X, Mao J, Mao C, Ye Y, et al: CPSF7 regulates liver
cancer growth and metastasis by facilitating WWP2-FL and targeting
the WWP2/PTEN/AKT signaling pathway. Biochim Biophys Acta Mol Cell
Res. 1867:1186242020. View Article : Google Scholar
|
|
129
|
Liu Y, Xu Q, Deng F, Zheng Z, Luo J, Wang
P, Zhou J, Lu X, Zhang L, Chen Z, et al: HERC2 promotes
inflammation-driven cancer stemness and immune evasion in
hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin
Cancer Res. 42:382023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zheng Y, Li J, Pan C, Zhou G, Zhuge L, Jin
L and Fang P: HERC4 is overexpressed in hepatocellular carcinoma
and contributes to the proliferation and migration of
hepatocellular carcinoma cells. DNA Cell Biol. 36:490–500. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Huang F, Tang X, Sun T, Wang G, Ru Q and
Zheng Y: SAV1, regulated by HERC4, inhibits the proliferation,
migration, and invasion of hepatocellular carcinoma. Transl Cancer
Res. 10:349–360. 2021. View Article : Google Scholar
|
|
132
|
Wang Y, Ding Q, Xu T, Li CY, Zhou DD and
Zhang L: HZ-6d targeted HERC5 to regulate p53 ISGylation in human
hepatocellular carcinoma. Toxicol Appl Pharmacol. 334:180–191.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Xue F, Higgs BW, Huang J, Morehouse C, Zhu
W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, et al: HERC5 is a
prognostic biomarker for post-liver transplant recurrent human
hepatocellular carcinoma. J Transl Med. 13:3792015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Yi J, Gong X, Yin XY, Wang L, Hou JX, Chen
J, Xie B, Chen G, Wang LN, Wang XY, et al: Parthenolide and arsenic
trioxide co-trigger autophagy-accompanied apoptosis in
hepatocellular carcinoma cells. Front Oncol. 12:9885282022.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Cai JB, Shi GM, Dong ZR, Ke AW, Ma HH, Gao
Q, Shen ZZ, Huang XY, Chen H, Yu DD, et al: Ubiquitin-specific
protease 7 accelerates p14(ARF) degradation by deubiquitinating
thyroid hormone receptor-interacting protein 12 and promotes
hepatocellular carcinoma progression. Hepatology. 61:1603–1614.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Jiang JH, Liu YF, Ke AW, Gu FM, Yu Y, Dai
Z, Gao Q, Shi GM, Liao BY, Xie YH, et al: Clinical significance of
the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by
exome sequencing. Hepatology. 59:2216–2227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Tao J, Liu Z, Wang Y, Wang L, Yao B, Li Q,
Wang C, Tu K and Liu Q: MiR-542-3p inhibits metastasis and
epithelial-mesenchymal transition of hepatocellular carcinoma by
targeting UBE3C. Biomed Pharmacother. 93:420–428. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Liu K, Tian F, Chen X, Liu B, Tian S, Hou
Y, Wang L, Han M, Peng S, Tan Y, et al: Stabilization of TGF-β
receptor 1 by a receptor-associated adaptor dictates feedback
activation of the TGF-β signaling pathway to maintain liver cancer
stemness and drug resistance. Adv Sci (Weinh). 11:e24023272024.
View Article : Google Scholar
|
|
139
|
Li S, Yan L, Li C, Lou L, Cui F, Yang X,
He F and Jiang Y: NPC1 controls TGFBR1 stability in a cholesterol
transport-independent manner and promotes hepatocellular carcinoma
progression. Nat Commun. 16:4392025. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ning J, Ye Y, Bu D, Zhao G, Song T, Liu P,
Yu W, Wang H, Li H, Ren X, et al: Imbalance of TGF-β1/BMP-7
pathways induced by M2-polarized macrophages promotes
hepatocellular carcinoma aggressiveness. Mol Ther. 29:2067–2087.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Feng X, Jia Y, Zhang Y, Ma F, Zhu Y, Hong
X, Zhou Q, He R, Zhang H, Jin J, et al: Ubiquitination of UVRAG by
SMURF1 promotes autophagosome maturation and inhibits
hepatocellular carcinoma growth. Autophagy. 15:1130–1149. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Dong L, Wei X, Yu L, Li Y and Chen L:
Inhibition of SIRT7 promotes STAT1 activation and STAT1-dependent
signaling in hepatocellular carcinoma. Cell Signal. 114:1110052024.
View Article : Google Scholar
|
|
143
|
Yang L, Tan W, Wang M, Wei Y, Xie Z, Wang
Q, Zhang Z, Zhuang H, Ma X, Wang B, et al: circCCNY enhances
lenvatinib sensitivity and suppresses immune evasion in
hepatocellular carcinoma by serving as a scaffold for SMURF1
mediated HSP60 degradation. Cancer Lett. 612:2174702025. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zhang W, Du D, Lu H, Zhang D, Liu L, Li J,
Chen Z, Yu X, Ye M, Wang W, et al: FAT10 mediates the
sorafenib-resistance of hepatocellular carcinoma cells by
stabilizing E3 ligase NEDD4 to enhance PTEN/AKT pathway-induced
autophagy. Am J Cancer Res. 14:1523–1544. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zeng Y, Jiang H, Chen Z, Xu J, Zhang X,
Cai W, Zeng X, Ma P, Lin R, Yu H, et al: Histone lactylation
promotes multidrug resistance in hepatocellular carcinoma by
forming a positive feedback loop with PTEN. Cell Death Dis.
16:592025. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Tong HV, Hoan NX, Binh MT, Quyen DT, Meyer
CG, Hang DTT, Hang DTD, Son HA, Van Luong H, Thuan ND, et al:
Upregulation of enzymes involved in ISGylation and ubiquitination
in patients with hepatocellular carcinoma. Int J Med Sci.
17:347–353. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Qin Y, Wang CJ, Ye HL, Ye GX, Wang S, Pan
DB, Wang J, Shen HJ and Xu SQ: WWP2 overexpression inhibits the
antitumor effects of doxorubicin in hepatocellular carcinoma. Cell
Biol Int. 46:1682–1692. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Zhao L, Ma H, Jiang Y, Li Y, Qiao L, Chen
Y, Jiang X, Wang L, Wang S and Fan X: Identification of an m6A
natural inhibitor, lobeline, that reverses lenvatinib resistance in
hepatocellular tumors. J Nat Prod. 87:1983–1993. 2024. View Article : Google Scholar : PubMed/NCBI
|
